2023-503368-18-00已完成1 期
A study to learn how safe the study treatment BAY2701250 is, how it affects the body and how it moves into, through and out of the body in healthy male participants when a single amount is given as an injection into the vein (intravenous infusion) or under the skin (subcutaneous injection).
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer AG
- 入组人数
- 91
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Therapeutic Area Head
Scientific
Bayer AG
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A study to learn how safe the study treatment BAY3401016 is, how it affects the body and how it moves into, through, and out of the body when a single amount is given to healthy male participantsAlport syndrome2022-502319-12-00Bayer AG126
招募中
1 期
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC2024-511956-42-00AstraZeneca AB44
已完成
1 期
Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer2024-518852-22-00Nelum Corp.28
招募中
不适用
Safety and efficacy of BAY 3283142 in patients with chronic kidney disease (ALPINE 1)Chronic kidney diseasejRCT2031240249Bayer Yakuhin, Ltd.700
招募中
1 期
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77